Paper36966238
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.
Dsouza NN and 5 others. Inflammopharmacology, 2023. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. Papers, record 36966238. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966238
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Idiopathic Pulmonary Fibrosis | Major topic |
| Thalidomide | Major topic |
| Immunosuppressive Agents | Major topic |
| Humans | |
| Inflammation | |
| Lung | |
| Transforming Growth Factor beta |
Source PubMed
References138
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36206625 | The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling. | EBioMedicine | 2022 | https://conductscience.org/library/papers/36206625 | PubMed |
| 2 | 28283856 | Effects of nintedanib on the microvascular architecture in a lung fibrosis model. | Angiogenesis | 2017 | https://conductscience.org/library/papers/28283856 | PubMed |
| 3 | 27577879 | Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. | J Allergy Clin Immunol | 2016 | https://conductscience.org/library/papers/27577879 | PubMed |
| 4 | 36044102 | Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. | Inflammopharmacology | 2022 | https://conductscience.org/library/papers/36044102 | PubMed |
| 5 | 33249990 | A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. | J Oncol Pharm Pract | 2021 | https://conductscience.org/library/papers/33249990 | PubMed |
| 6 | 23810410 | Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice. | Int Immunopharmacol | 2013 | https://conductscience.org/library/papers/23810410 | PubMed |
| 7 | 24950782 | Thalidomide ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in an experimental model. | Inflammation | 2015 | https://conductscience.org/library/papers/24950782 | PubMed |
| 8 | 21614166 | Thalidomide prevents the progression of peritoneal fibrosis in mice. | Acta Histochem Cytochem | 2011 | https://conductscience.org/library/papers/21614166 | PubMed |
| 9 | 31591562 | p63 is a cereblon substrate involved in thalidomide teratogenicity. | Nat Chem Biol | 2019 | https://conductscience.org/library/papers/31591562 | PubMed |
| 10 | 31202702 | Molecular mechanisms of cereblon-based drugs. | Pharmacol Ther | 2019 | https://conductscience.org/library/papers/31202702 | PubMed |
| 11 | 32414180 | Molecular Mechanisms of the Teratogenic Effects of Thalidomide. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/32414180 | PubMed |
| 12 | 34165402 | Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs. | Curr Med Chem | 2022 | https://conductscience.org/library/papers/34165402 | PubMed |
| 13 | 30082599 | Idiopathic Pulmonary Fibrosis (IPF): An Overview. | J Clin Med | 2018 | https://conductscience.org/library/papers/30082599 | PubMed |
| 14 | 26196302 | Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. | Vascul Pharmacol | 2017 | https://conductscience.org/library/papers/26196302 | PubMed |
| 15 | 32822614 | Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. | Lancet Respir Med | 2021 | https://conductscience.org/library/papers/32822614 | PubMed |
| 16 | 26501392 | Involvement of cytokines in the modulation and progression of renal fibrosis induced by unilateral ureteral obstruction in C57BL/6 mice: effects of thalidomide and dexamethasone. | Fundam Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26501392 | PubMed |
| 17 | 30339882 | Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. | Free Radic Biol Med | 2018 | https://conductscience.org/library/papers/30339882 | PubMed |
| 18 | 36088459 | Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis. | Nat Commun | 2022 | https://conductscience.org/library/papers/36088459 | PubMed |
| 19 | 28074423 | Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention. | Drug Saf | 2017 | https://conductscience.org/library/papers/28074423 | PubMed |
| 20 | 29567124 | Endoplasmic reticulum stress in pulmonary fibrosis. | Matrix Biol | 2018 | https://conductscience.org/library/papers/29567124 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42959490 | Cardiovascular Risk of Conventional Synthetic, Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Common Rheumatic Diseases: A Narrative Review of Current Evidence. | Ther Clin Risk Manag | 2026 | https://conductscience.org/library/papers/42959490 | PubMed |
| 42840583 | Cereblon promotes influenza A virus replication through AMPK ubiquitination. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42840583 | PubMed |
| 42794640 | Bicyclol: A Useful Agent for Silicosis? | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794640 | PubMed |
| 42650379 | Image-Based Assessment of Anti-TNF Treatment Outcomes in Pediatric CRMO/CNO: A Single-Center Case Series. | Children (Basel) | 2026 | https://conductscience.org/library/papers/42650379 | PubMed |
| 41860320 | Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/41860320 | PubMed |
| 41585259 | Comparison of the efficacy of thalidomide combined with low-dose rituximab and low-dose rituximab alone in the treatment of steroid-resistant/refractory adult patients with primary immune thrombocytopenia: an open-label trial. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41585259 | PubMed |
| 41416432 | Aggravated effects of human parvovirus B19 NS1 protein on bleomycin‑induced pulmonary fibrosis. | Mol Med Rep | 2026 | https://conductscience.org/library/papers/41416432 | PubMed |
| 41361355 | Network pharmacology and in vitro studies demonstrate modulation of fibrotic pathways by Swertia chirayita in pulmonary fibrosis. | Sci Rep | 2025 | https://conductscience.org/library/papers/41361355 | PubMed |
| 41304934 | Renaissance of Phoenix Drug Thalidomide-New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304934 | PubMed |
| 39872463 | MSC-derived exosome ameliorates pulmonary fibrosis by modulating NOD 1/NLRP3-mediated epithelial-mesenchymal transition and inflammation. | Heliyon | 2025 | https://conductscience.org/library/papers/39872463 | PubMed |
| 39639365 | Biological and pharmacological roles of pyroptosis in pulmonary inflammation and fibrosis: recent advances and future directions. | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/39639365 | PubMed |
| 39519747 | Co-Mn Complex Oxide Nanoparticles as Potential Reactive Oxygen Species Scavenging Agents for Pulmonary Fibrosis Treatment. | Molecules | 2024 | https://conductscience.org/library/papers/39519747 | PubMed |
| 39005763 | Integrated ML-Based Strategy Identifies Drug Repurposing for Idiopathic Pulmonary Fibrosis. | ACS Omega | 2024 | https://conductscience.org/library/papers/39005763 | PubMed |
Genes70
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36966238
GET https://conductscience.org/api/papers/v1/36966238/references?page=2